Memory Pharmaceuticals Corp. (NASDAQ:MEMY)
Industry: Healthcare
Memory Pharmaceuticals Corp., incorporated on March 19, 1997, is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of a range of central nervous system (CNS) conditions, many of which exhibit significant impairment of memory and other cognitive functions. These conditions include neurological diseases associated with aging, such as Alzheimer's disease, and also include certain psychiatric disorders, such as schizophrenia, bipolar disorder and depression. The drug development pipeline includes four programs (an L-type calcium channel modulator, nicotinic alpha-7 agonists, PDE4 inhibitors and PDE10 inhibitors) with drug candidates in clinical and preclinical stages, and several other compounds with potential in the early-stage pipeline. The products, designed for oral dosing, are MEM 1003 for the treatment of Alzheimer's disease and bipolar disorder; MEM 3454 for schizophrenia and/or Alzheimer's disease; MEM 1414 for Alzheimer's disease; MEM 1917 for Alzheimer's disease and depression; MEM 63908 for Alzheimer's disease, and MEM 63908 for Alzheimer's disease. The Company is focused on the discovery and development of CNS drugs impacting biological targets that play a role in memory formation and cognition and which may also be implicated in other CNS conditions, such as bipolar disorder. It is targeting specific subcategories of neurotransmitter receptors, specific enzymes that regulate second messengers and protein channels that modulate the flow of second messengers, such as calcium. Memory Pharmaceuticals Corp. has collaborations with F. Hoffman - La Roche Ltd. / Hoffman - La Roche, Inc., or Roche, one for the development of PDE4 inhibitors, and the other for the development of nicotinic alpha-7 agonists. In addition to preclinical and clinical drug candidates, the Company is testing a number of compounds in vitro and in animal models for efficacy, safety and toxicity. The pipeline includes additional compounds that are being explored for the treatment of Alzheimer's disease, schizophrenia and depression. MEM 1003 MEM 1003, a CNS-optimized dihydropyridine, is a neuronal L-type calcium channel modulator that is being developed for the treatment of Alzheimer's disease. By blocking L-type calcium channels, MEM 1003 may regulate the flow of calcium. Preclinical tests of MEM 1003 in vitro, as well as in animal models have been conducted. In invitro tests, MEM 1003 significantly blocked and regulated the function of neuronal L-type calcium channels in brain slices and single-cell cultures. In the animal tests, MEM 1003 improved memory and learning. In September 2005, a Phase 1b safety and tolerability study in patients with Alzheimer's disease was completed under a United States Investigational New Drug (IND) application, known as Phase 1b safety and tolerability study. MEM 1003 was safe and generally well tolerated in the study. In November 2005, Memory Pharmaceuticals commenced a Phase IIa multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two dose levels of MEM 1003 in approximately 180 patients with mild to moderate Alzheimer's disease under IND, known as Phase IIa AD clinical trial, which is expected to be completed in the first half of 2007. MEM 3454 MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor being developed as a potential therapy for schizophrenia and/or Alzheimer's disease. Studies have shown that schizophrenic patients can experience relief of symptoms through the administration of nicotine, which binds to nicotinic receptors. One of the nicotinic receptors is the nicotinic alpha-7 receptor, a highly specialized receptor found in the CNS, particularly in the hippocampal region of the brain. This receptor modulates neurotransmitter activity known to be required for the formation of long-term memories. The products has demonstrated efficacy in several preclinical animal models of schizophrenia and generated positive results in preclinical models of antipsychotic drug action, in
As Of: 10/07 00:00 ET
*Quotes delayed by 20min.
BuyIns.Net Alerts for Symbol MEMY
- No BuyIns.Net Alerts Available for MEMY
Graphs for MEMY
3 Month Graph
6 Month Graph
1 Year Graph
